Form 8-K - Current report:
SEC Accession No. 0001558370-25-000159
Filing Date
2025-01-13
Accepted
2025-01-13 09:21:55
Documents
13
Period of Report
2025-01-13
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K ymab-20250113x8k.htm   iXBRL 8-K 31716
  Complete submission text file 0001558370-25-000159.txt   151154

Data Files

Seq Description Document Type Size
2 EX-101.SCH ymab-20250113.xsd EX-101.SCH 3413
3 EX-101.LAB ymab-20250113_lab.xml EX-101.LAB 15928
4 EX-101.PRE ymab-20250113_pre.xml EX-101.PRE 10320
15 EXTRACTED XBRL INSTANCE DOCUMENT ymab-20250113x8k_htm.xml XML 4845
Mailing Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169
Business Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 212-847-9841
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

EIN.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38650 | Film No.: 25525088
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)